CXCR4 and hematologic disorder: Among multiple CXCR4 inhibitors available for research, only AMD3100 (also known as plerixafor) has been approved for the induction of autologous hematopoietic stem cell (HSC) mobilization in patients with hematological malignancies (see ‘targeting the niche’).